NCT02039089View on ClinicalTrials.gov

A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Healthy Volunteers
Interventions
DRUG

E2006 2.5 mg

DRUG

E2006 10 mg

DRUG

E2006 25 mg

DRUG

Placebo

Trial Locations (1)

Unknown

Glendale

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT02039089 - A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects | Biotech Hunter | Biotech Hunter